Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Acquired by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA boosted its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 11.5% in the 4th quarter, HoldingsChannel reports. The firm owned 18,900 shares of the biopharmaceutical company’s stock after purchasing an additional 1,946 shares during the period. Pictet Asset Management Holding SA’s holdings in Halozyme Therapeutics were worth $904,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Heck Capital Advisors LLC purchased a new stake in shares of Halozyme Therapeutics during the fourth quarter worth about $29,000. CBIZ Investment Advisory Services LLC purchased a new stake in Halozyme Therapeutics in the 4th quarter worth approximately $29,000. Smartleaf Asset Management LLC raised its holdings in Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 197 shares during the last quarter. Venturi Wealth Management LLC purchased a new position in shares of Halozyme Therapeutics during the 4th quarter worth $69,000. Finally, Parkside Financial Bank & Trust lifted its stake in shares of Halozyme Therapeutics by 21.8% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 322 shares during the period. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Price Performance

HALO opened at $59.77 on Monday. Halozyme Therapeutics, Inc. has a 52-week low of $37.73 and a 52-week high of $66.00. The company has a 50 day moving average of $59.82 and a two-hundred day moving average of $54.82. The company has a market cap of $7.38 billion, a P/E ratio of 17.43, a P/E/G ratio of 0.42 and a beta of 1.32. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The firm had revenue of $298.01 million during the quarter, compared to analysts’ expectations of $285.74 million. On average, analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Analysts Set New Price Targets

HALO has been the subject of several analyst reports. Piper Sandler upped their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Benchmark reissued a “buy” rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Finally, Wells Fargo & Company dropped their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $62.78.

Insider Activity

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 1,697 shares of Halozyme Therapeutics stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the sale, the senior vice president now directly owns 173,756 shares in the company, valued at $10,126,499.68. The trade was a 0.97 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffrey William Henderson sold 503 shares of the company’s stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $64.05, for a total transaction of $32,217.15. Following the completion of the sale, the director now directly owns 33,108 shares in the company, valued at $2,120,567.40. This represents a 1.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 22,200 shares of company stock worth $1,286,568. 2.90% of the stock is currently owned by corporate insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.